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Classical end-points in clinical therapeutic trials in oncology
are usually defined by total, recurrence-free or systemic
disease-free survival. Primarily, these allow an adequate de-
scription of the biological course of the disease. In current
oncological research advances in the treatment of cancer
patients as measured by these end-points must realistically be
assumed to be only of a rather small magnitude. This implies,
on the one hand, that prospectively only by large-scale multi-
centre trials and retrospectively only by meta-analyses of
comparable trials can sufficient numbers of patients be
reached to allow a detection of treatment benefits of a realis-
tic size. On the other hand, if treatments do not differ much
with respect to survival, it is a plausible step forward to
extend the classical criteria of assessing treatment efficacy. It
is undisputed that the disease and its treatment have an
influence on all aspects of a cancer patient's life. Although
physicians had previously recorded the occurrence of toxic
reactions possibly induced by cancer treatment, it was not
until the 1940s that with their pioneering work Karnofsky et
al. (1948) made a first attempt to quantify the performance
status of patients with advanced cancer. In the following
decades there has been increasing realisation of the need to
achieve a more comprehensive evaluation of treatment
efficacy beyond the objective aspects of achieving optimal
survival, maximal tumour response and minimal toxicity
(Maguire & Selby, 1989). In attempting to reach this goal,
additional end-points in cancer clinical trials were introduced
that take into account the subjective response of the patients
to their illness and its treatment. The sum of aspects of the
patients' subjective well-being is most often caHled 'quality of
life' (QoL) (e.g. Tchekmedyian & Cella, 1990).
Concept and evaluatio, ofQoL
Although each individual usually has an intuitive under-
standing of what quality of life means for him or her, no
general and unique definition of QoL is regarded as possible
or even sensible. Cella and Tulsky (in Tchekmedyian & Cella,
1990) honestly admit that 'QoL cannot be validly measured,
because it means so many different things to so many
different people'. This is especially true for the extraordinary
life situation of persons who have faced the often life-
threatening diagnosis of cancer.
Instead of trying to elaborate an analytical definition, QoL
is introduced into clinical research by means of a so-called
operational construct, recognising that an individual's life
and its corresponding quality cannot be quantified in an
objective way. Instead, and rather pragmatically, a patient's
QoL is quantified using measurements obtained from a set of
sensibly defined, quantifiable dimensions. The major points
of agreement among QoL researchers on this construct can
be summarised by the statements that QoL is:
1. multidimensional, comprising important elements of a
patient's emotional, social and physical well-being;
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2. subjective, relying primarily on the patient s own
judgements; and
3. non-static and subject to changes over a patient's lifetime.
The most basic approach to a QoL assessment would be to
ask the patient only a briefquestion such as: 'How have you
been doing lately?' Although such an approach is appealing
because of its simplicity, it will prevent the detection of the
reasons for a patient's good or bad well-being. A global
question seems informative only as a patient's final, global
summary after a more detailed assessment. Instead, point (1)
leads to the requirement that QoL has to be decomposed into
its major aspects, each of which can be sufficiently con-
cretised for an evaluation in patients. A suitable measuring
instrument should account for the multidimensionality of
QoL by adequately covering all the major dimensions. For
example, the psychological dimension can include aspects
such as anxiety, depression, mood, etc. The social dimension
is represented by aspects such as the relations to other per-
sons and the fulfilnent with activities in leisure time. Physical
well-being covers the patient's appraisal of his/her somatic
reactions to disease and treatment. The performance status is
characterised by the ability of the patient to perform daily
tasks such as going to work, housework, etc. This division of
QoL into several different aspects does not preclude that
there may be interdependencies between them; aspects of
physical well-being such as, for example, alopecia after
chemotherapy will also influence aspects of emotional and
social well-being in many patients. Each of these aspects can
be ass in a rather formal and objective way using
measuring instruments that have been borrowed from social
sciences, such as structured interviews or self-assessment
questionnaires.
The second point of the QoL construct seems rather
obvious, but it has taken some time to become accepted that,
whenever possible, the individual patient is the principal
authority to be asked about his/her QoL. Physician's assess-
ment of the patients' QoL, which was widely practised when
QoL methodology was introduced, has proved to be less
reliable when used exclusively (Slevin et al., 1988; Regan et
al., 1991). It is undisputed that a detailed interview is the
most appropriate approach to comprehensively evaluate an
individual's well-being. However, the most feasible form of a
measuring instrument in the context of multicentre trials is
the self-administered questionnaire. A good questionnaire is
characterised by possessing certain so-called 'psychometric'
standards like validity (measuring what is intended to be
measured), reliability (measuring with sufficient precision)
and sensitivity (ability to detect changes).
The last is important especially in the light of point (3) of
the QoL construct. A person's QoL is subject to changes
over time, reflecting, for example, the patient's ability to cope
with the disease or the experiences with different treatment
modalities. Therefore, an adequate evaluation of QoL is
necessary at more than two points in time to be able to
assess both short- and long-term effects of treatments.
Because of the need to establish and use valid and reliable
measuring instruments, the adoption of any pre-existing
validated questionnaires should be preferred over the
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development of new ad hoc questionnaires. If one feels that
important specific aspects are missing in a particular ques-
tionnaire, it is in most cases possible to add additional
components to the existing measuring instrument without
changing its original structure.
A prominent example of an established QoL questionnaire
advocated for use in cancer clinical trials by Maguire and
Selby (1989) is the Rotterdam symptom checklist (RSCL;
deHaes et al., 1990). This self-assessment questionnaire con-
tains 30 items asking patients how they have experinced
particular aspects of well-being over the last week. The an-
swers to each item are scored on a four-point ordinal rating
scale with categories ranging from 'not at all' to 'very much'.
Related questions can be summarised into two major sub-
scores representing a patient's physical and psychological
well-being. Enxamples of questions from the different sub-
scores of the RSCL are displayed in Table I. The authors
claim that it is possible to extend the RSCL with necessary
additional items, especially for the underrepresented area of
social well-being. Studies are currently under way to inves-
tigate the applicability of the RSCL in an international,
longitudinal setting (deHaes et al., 1994). An Italian version
of the RSCL has already been validated and proved useful in
clinical research (Pad, 1992).
Another important measung instrument has been under
development by the European Organisation on Research on
Treatment of Cancer (EORTC; Aaronson et al., 1993). Their
self-assent questionnaire is based on a modular ap-
proach always including a core questionnaire (QLQ-C30)
comprising items related to general aspects of well-being
which are deemed valid for a broad range of patients with
different types of cancer. The QLQ-C30 includes five func-
tional scales (physical, role, cognitive, emotional and social),
three general symptom scales (fatigue, pain and nausea/
vomiting), several single-item symptom measures, one global
health and one global quality-of-life item. The rating of each
item is on either a two- or four-point scale using verbalised
categories. The QLQ-C30 is supplemented by a module with
tumour-specific items. A nine-item version for lung cancer
patients has been developed, and others are to follow
(Aaronson et al., 1988). The main advantage of the modular
approach is the possibility of allowing sensible comparisons
of results between QoL trials on the basis of the same core
questionnaire. These can also serve as a sound basis for
performing meta-analyses of comparable QoL trials. In that
sense the QLQ-C30 possesses the additional advantages of
being conceptualised as an international cross-cultural
measurng istrument that has been tested in 13 different
countries and of having been developed specifically for use
with cancer patients.
CoIectioel ofQoL data
The assessment of QoL as an important end-point in cancer
clinical trials will usually be performed paralkl to the record-
ing of the classical clinical end-points. As a consequence the
number of data to be coLected within a trial will inevitably
increase. Therefore, especially in large multicentre tnals, the
practicability of the QoL measuring instrument is of primary
importance to achieve suffikient numbers of partwipating
centres and patients. Although it may be tempting to gather
Table I Selected items from the Rotterdam symptom checklist
(RSCL)
Have you,during the past week, been botheredby
Tiredness? Not at all A little Quite a bit Very much
Nausea? Not at all A little Quite a bit Very much
Abdominal aches? Not at all A little Quite a bit Very much
Worrying? Notat all Alittle Quitea bit Verymuch
Anxiety? Not at all A little Quite a bit Very much
Depressed mood? Not at all A little Quite a bit Very much
as much information as possible to account for the multi-
dimensional character of QoL, for reasons of feasibility the
questionnaire should be kept as simple and short as possible.
Bearing in mind the medical condition of the patient popula-
tion it is desirable to concentrate on not more than 50
colloquially formulated questions that each patient can easily
answer without assistance and within a short time.
Emphasis must be put on achieving acceptance of the
importance of the QoL assessment among all the par-
ticipating centres, because additional data collction intro-
duces an extra burden for the medical staff. The participating
clinicians should be convinced that the QoL assesment is not
just a 'fashionable' add-on, but a serious end-point of a trial.
Guidelines for the administering of the questionnaires that
also include the rationale for the QoL assessment have
proved helpful in this context.
QoL assessments should be tied in with the routine clinical
follow-up schedule for the triaL which for avoidance of bias
should be at the same times for all treatment arms. However,
some flexibility with a preplanned time schedule may some-
times be appropriate. If, for example, in a chemotherapy trial
a QoL assessment has been planned at some fixed time point
corresponding to the regular end oftreatment, but there have
been delays in some patients because oftoxic side-effects, it is
better to defer the QoL assessment to the actual end of
treatment in these patients instead ofadhering to a rigid time
frame.
During the conduct of the trial, continuous monitoring of
data quality and especially the patients' compliance with
QoL assments is mandatory to enable immediate interven-
tion in case of missing or incomplete data.
One of the most severe sources of bias that may be intro-
duced in a clinical trial is non-compliance of patients, either
by dropping out of the trial completely or by refusing to
participate in the QoL assessment. The magnitude of this
bias will depend strongly on the reasons for dropping out. If,
for example, advancing disease prevents patients par-
ticipating in the QoL assessment, consideration of only the
responding patients might lead to a too optimistic assessment
of QoL in that trial. One might even thinkl of an extreme
scenario of an ineffective treatment not preventing disease
progression, and leading to a deterioration of patients' well-
being, which the patients are no longer capable ofdocument-
ing on a QoL form. Owing to their non-compliance these
patients would not contribute to the analysis of QoL. Com-
pared with a treatment that is effective but induces side-
effects that reduce the well-being, but not so severely that the
patients refuse QoL assessment, an analysis based on the
available QoL forms may falsely lead to declaring the worse
treatment superior.
Generally, this bias can at best be reduced by using a
short, clearly formulated questionnaire with ordinal, ver-
balised answer categories that can be completed without
much additional effort in a short time. Within a multicentre
clinical trial the practicability of the QoL assessment for the
individual patient should be one of the major goals, being as
important as the demand for psychometric properties of the
questionnaire. Many patients do not regard feasible QoL
assessment as an extra burden, but rather have a positive
attitude to being questioned about their well-being (Aaron-
son et al., 1993), which in itself may also positively influence
the doctor-patient relationship.
An example of a trial that used QoL as a primary end-
point, but failed to produce statistically evaluable data, was
published by Ganz et al. (1988). In this randomised trial two
treatments for metastatic lung cancer patients were compared
using the functional living index of cancer (FLIC) as the
QoL measure (Schipper et al., 1984). Of 63 patients entered
into the trial, two were totally lost to follow-up, while 15
refused the QoL assessment. Of the remainder, six had not
completed baseline forms, so there were 40 (63%) evaluable
patients. Furthermore, 16 patients had at least one missing
value out of the 22 items. Although the FLIC is to be
self-administered by the patient, only 110 (58%) out of 189
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bably because of advancement of the disease the percentage
of self-administered questionnaires was 70% at baseline and
declined steadily over time. The reasons the authors give for
their low compliance rates were organisational problems, as
well as a declining performance status of some patients over
time. The authors rightly concluded that it would not be
sensible to perform statistical analyses of the QoL data in
such a situation. Another example of poor compliance with
QoL assessment was reported by the Swiss Group for
Clinical Cancer Research (Hurny et al., 1992), who called it
'a lesson from the real world'. Their multicentre trial com-
paring two different regimens of combination chemotherapy
in patients with small-cell lung cancer recruited 188 patients.
QoL was assessed with three questionnaires, including an
earlier version of the EORTC QLQ-C30. Their compliance
rates vaned between 37% and 58% over each of the six
cyc4es and between 21% and 68% among the seven par-
ticipating institutions. Both examples illustrate how non-
acceptance of QoL assessment by physicians and patients in
a clinical tnral can lead to an intolerable amount of missing
data preventing any sensible statistical analysis.
By contrast, extremely high compliance rates have been
reported by the Canadian Clinical Trials Group (Sadura et
al., 1992) from three of their currently ongoing trials on
malignant melanoma, breast cancer and on the effects of two
antiemetics. They instituted a set ofspecific measures prior to
trial activation to ensure maximum response of the QoL
questionnaires including, for example, completion of QoL
questionnaire as an eligibility criterion and implementation
of pretrial workshops for the medical staff on the rationale
and procedure of QoL collection. By means of these efforts,
more than 95% of the scheduled QoL questionnaires were
returned, and on these more than 99% of the questions were
answered in all three trials.
Hurny et al. (1992) have provided an excellent overview of
the most important practical guidelines for a successful
implementation of QoL assessments.
Statstcal analysis and interpretation
Usually, a QoL questionnaire consists of a number of ques-
tions. The procedure of exlaminng differences between
groups of patients or changes over time by using each item
separately leads to the well-known methodological problem
of inflated significance levels due to multiple testing. An
adequate adjustment of the significance level of each test or a
combination of individual test s4atistics into a global statistic
is then essential. However, interpretation remains a serious
problem.
A preferable approach is to use statistical methods to
analyse QoL data which account for their multidimensional
nature and provide techniques to condense the information
into global indices of special QoL aspects such as emotional,
social and physical well-being. The simplest approach to
combining questions would be to calculate an overall total of
all questions of a QoL questionnaire to yield a single QoL
score for each patient. This can be criticised as providing an
oversimplified assessment of a patient's QoL. A simple
additive combination of possibly heterogeneous aspects of
QoL can lead to low ratings in some questions cancelling out
high ratings in others. Therefore, before comparing groups of
patients with respect to QoL, the large number of questions
should be reduced to a smaller number of global, but sen-
sibly interpretable, indices. An index is the aggregation of
questions that are closely related to a particular dimension of
QoL. These indices are calculated either on the basis of some
form of expert rating or, preferably, using data obtained
from a representative sample of cancer patients. Multivariate
statistical procedures, such as factor analysis, are applied to
the data to detect correlation structures among the questions
and then to allow items to be combined into scores that can
be regarded as representing different dimensions ofQoL. For
example, for the Rotterdam symptom checklist factor
analytical techniques confirmed two major subscales which
can be interpreted as the physical and the psychological
dimension of QoL (deHaes et al., 1990). The results of such
an analysis may also be used to obtain estimates for the
relative importance that patients attach to the different ques-
tions of the questionnaire.
In a chronic disease like cancer it is not sufficient to assess
QoL at only one point in time, because we have to assume
changes of QoL over time. Repeated measurements on the
individual must be regarded as essential for an adequate
assessment of QoL in cancer clinical trials. It is commonly
accepted that QoL should be assessed before treatment, if
possible or sensible, as well as during and directly after
treatment, to account for short-term effects, and some time
after treatment, to account for late effects.
Three principal questions need to be answered by an
analysis of QoL data over time. First there is the central
question of a global difference between treatment and/or
prognostic subgroups with respect to QoL. The second ques-
tion is whether there is a global change of QoL in time in
relation to an improvement or deterioration of the patients'
well-being. The third question is whether there is differential
change of QoL among patients after different treatments or
in different prognostic subgroups. The latter could occur if,
for example, an aggressive treatment leading to a poor QoL
immediately after the start of treatment turns out beneficial
for the patients' well-being in the long run.
Statistical methods for the analysis ofQoL data should not
assume the independence of repeated QoL measurements
over time on the same individual. Measurements made at
adjacent time points can be expected to be positively cor-
related, especially within shorter time intervals during which
QoL is not expected to change drastically. This implies the
use of analysis of variance and covariance for repeated
measurements when QoL scores can be assumed to be nor-
mally distributed (Zee & Pater, 1991) and generalised linear
models otherwise (Agresti, 1989). Zwinderman (1990) pre-
sented a simple version of such a longitudinal model for the
comparison of the effect of two different treatments on the
QoL of breast cancer patients with bone metastases. From
his QoL measurements he reduced each different aspect of
QoL (mobility, toxicity, pain and psychological distress) to
the binary outcome of 'good' or 'bad' QoL and proposed a
model assuming that the probability of observing a patient in
a 'good' QoL state at a certain point in time depends on a
baseline level characterising the individual patient, a treat-
ment effect and a time effect, the last two being assumed to
be the same for all patients. For the functional relationship
between the probability of having 'good' QoL and certain
clinical covariates he used a logistic regression model.
A serious problem that occurs in a longitudinal analysis is
missing QoL data for patients who have died or dropped out
of the trial. There is no straightforward way to handle this
problem, but it is obvious that not including these patients in
an analysis is likely to lead to biased estimates. Zwinderman
(1992) suggests imputing mean values, calculated from
available patients, for missing values under the often
unrealistic assumption that QoL data is missing at random.
In clinical oncological research principal interest centres
around the times from diagnosis or randomisation to an
end-point such as death or tumour relapse, and the data
are analysed using techniques of survival analysis (e.g.
Kaplan-Meier product limit estimate, Cox's proportional
hazards regression model). From the viewpoint of survival
analysis it seems appealing to combine length of survival, the
classical end-point, and QoL into a single end-point, which is
most often described as quality-adjusted life years (QUALY)
or quality-adjusted survival (QAS). This can be defined by
multiplying each period of the individual survival time by a
weight corresponding to the patient's QoL during this period
and then summing these weighted times. In this context
recurrence-free survival time can be regarded a special case of
a QAS with time from tumour removal until the time of first
occurrence of a relapse receiving a weight of 1, and the time
after relapse receiving a weight of 0. The most elaborate and
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research has been presented by Gelber et al. (1986) by their
definition of TWiST (time without symptoms and toxicity).
For this purpose they subtracted from individual survival
times of patients with advanced breast cancer those months
in which the patient experienced or recovered from severe
side-effects of local surgical procedures. This can also be
considered as attaching a weight of1 for those survival times
a patient is both disease-free and not suffering from severe
side-effects and 0 otherwise. Goldhirsch et al. (1989) later
modified TWiST into Q-TWiST (quality-adjusted TWiST)
allowing the attachment of positive weights between 0 and 1
to the survival times of a patient spent in toxicity and after
recurrence. The choice of suitable weights that correspond to
an adequate assessment of QoL is still the subject of con-
troversial discussion.
An intuitive approach to analyse these QAS times would
be an application of standard methods of survival analysis.
However, if censored observations are present, e.g. patients
have not yet reached the end-point of interest at the time of
analysis, as is usual in survival data, the use of individually
calculated QAS can lead to serious biases in the analysis.
Glasziou et al. (1990) have shown that transforming the
natural time scale to a QAS time scale introduces informative
censoring. The reason for this is that patients with low QoL
will accumulate their QAS time only very slowly, therefore
censoring will occur earlier in these patients than in those
with a higher QoL. A proposed solution to this problem is
not to calculate QAS times for the individual patient, but
instead to estimate mean times of staying in a particular QoL
state and then attach the QoL weights to these collective
means. Unbiased treatment comparisons can be performed
on the basis of these quality-adjusted mean survival times.
Adjustment for the effects of additional clnical covariates by
applying Cox's proportional hazards model has also been
investigated for this situation (Cole et al., 1993).
Co.ch.ioa and MscmNM
The formal assessment of QoL of cancer patients in addition
to 'hard' clinical data is becoming more and more accepted
in the medical community, as reflected for example in a
recent editorial in the British Medical Jornal demanding that
'cancer trials should include measures of patients' well-being'
(Byrne, 1992). The interest in QoL is demonstrated by the
increasing number of publications using QoL in the title or
as a keyword. In a literature survey (Schumacher et al., 1991)
coverng Cancer and the Journal of Clinical Oncology over
the 5 year period from 1985 to 1989, we found 73 such
papers, of which 45 (62%) were reports of clnical trials
claiming to have included QoL as an end-point of interest.
However, only 36% of these QoL trials (16 out of 45)
assessed QoL adequately. Eighteen per cent of the trials used
insufficient measuring instruments covenng only some aspects
of QoL (8 out of 45); the rest used at best only surrogate
end-points for QoL such as the time spent in hospital (21 out
of 45). These surrogate end-points are not unimportant, but
is it wrong to think that they assess QoL.
Although the above-mentioned findings are rather
negative, the achievements made in some of the trials that
adequately evaluated QoL have been quite remarkable. In
early breast cancer, for example, several trials have inves-
tigated the efficacy of breast-preserving treatment as com-
pared vith the standard treatment of mastectomy. The
results of these trials confirm that the two treatments can be
regarded as equally effective with respect to survival. With
regard to QoL, an overview of 18 studies conducted in this
area indicates that treating breast cancer patients with breast
preservation does not automatically coincide with a global
improvement of their QoL as compared with the standard
treatment of mastectomy (Kiebert et al., 1991). This result at
first seems rather surprising and counter to the often-stated
contrary opinion. A possible explanation is that the negative
effect that the cancer diagnosis produces on the patients'
QoL overrides the effect of both surgical treatments.
Similar unexpected results were reported with respect to
adjuvant treatment in cancer patients (Slevin, 1992). It is well
known that chemotherapy induces toxic side-effects in a large
proportion of patients, with the intensity of some of the
side-effects being proportional to the intensity of treatment.
However, QoL studies have found that a more intensive
treatment is not always associated with lower QoL despite
the obj'ective occurrence of more severe side-effects. A pos-
sible explanation here is that the experience of going through
a painful treatment provides more hope for a cure of the
disease in some patients, leading to a better toleration of
side-effects.
The results from these trials may serve as examples of the
need to not just believe one's own assumptions about
patients' QoL, but rather to let the patients assess their QoL
themselves.
The successful implementation of a QoL assessment in
large multicentre trials relies on the feasibility of the
measurement approach. Short, self-administered, but valid-
ated questionnaires covering the major aspects of QoL
should be used. The achievement of high-quality QoL data
should be given the same priority as clinical data, because
this is essential for adequate analysis and interpretation.
Once a trial is completed, it will be impossible to improve
poor data quality. Efforts to improve data quality, such as
those mentioned, should be considered in the planning and
implemented as part of the execution of a trial. It should be
emphasised to all trial participants that the evaluation of
QoL is more than just adding a new laboratory measure-
ment. As Ganz et al. (1988) noted, 'it is critically important
that QoL data are collected with the same care and detail as
are response and toxicity data'.
In our literature survey (Schumacher et al., 1991) we
reviewed the statistical methods used to analyse QoL data in
published trials. About one-third of the publications present-
ed solely a descriptive analysis of the data by reporting
frequencies, means and correlations. In about 50% of the
trials univariate parametric or non-parametric significance
tests were applied and multiple P-values reported. Although
QoL was measured at more than two points in time in about
40% of the publications, adequate methods to analyse QoL
over time were rarely used.
Although it is preferable to keep statistical methods as
simple as possible to allow an easy understanding of the
results, the complicated structure of QoL data often requires
sophisticated analyses. Using only elementary statistical pro-
cedures in situations where they are inadequate may yield
easily understandable, but also wrong, conclusions. However,
as the methods for assessing QoL become more sophis-
ticated, greater emphasis must be put into 'translating' the
numerical results into understandable information for
clinicians and patients to broaden the knowledge base for
future treatment decisions (Cox et al., 1992). For example,
interpretation of the values of QoL scores calculated by an
aggregation of different questions of a questionnaire may be
easier when presented as the percentage of the maximum
possible score instead of the raw values, and in addition
makes the results more independent of the mostly arbitrary
item scoring.
The proposal to combine quantity and quality of survival
into one new end-point such as QAS seems intuitively
appealing because end-points like total or recurrence-free
survival can be regarded as special cases. It also helps to
solve the problem of how to treat missing QoL data for those
patients that have died. But weighting a 'hard' end-point
with a 'soft' one does not create a new 'hard' end-point but
rather a 'medium' one, still leaving a lot of controversy.
It is rather difficult to propose a standard statistical
strategy to be adopted for an analysis of QoL data, because,
unlike the situation in survival analysis, there is no typical
kind of data set that calls for specific type of analysis. This is
also the reason why papers concerned with the analysis of
QoL data do not advocate fixed analysis plans (Schumacher
et al., 1991; Zee & Pater, 1991; Cox et al., 1992). Because of
the inherent 'softness' of QoL data it might be sensible tooffer more than one adequate analysis approach, enabling
interested readers to perform a sensitivity analysis for
themselves.
Assessing QoL in cancer patients has reached a sound
basis. Much effort has recently been put into the propagation
of the idea of including QoL measures routinely in clinical
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research (e.g. Fitzpatrick et al., 1992; Fletcher et al., 1992;
Slevin, 1992; Spieglehalter et al., 1992; Finlay & Dunlop,
1994), but still more efforts are needed in this direction. In
our view, the field of QoL evaluation requires further inten-
sive interdisciplinary collaboration of physicians, psycho-
social researchers and biostatisticians.
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